Lawsuit filed for Investors who lost money with shares of Kenvue Inc. (NYSE: KVUE)

An investor, who purchased shares of Kenvue Inc. (NYSE: KVUE), filed a lawsuit over alleged violations of Federal Securities Laws by Kenvue Inc. in connection with certain allegedly false and misleading statements made in connection with the Company's May 2023 initial public offering

Investors who purchased shares of Kenvue Inc. (NYSE: KVUE) have certain options and for certain investors are short and strict deadlines running. Deadline: December 8, 2023. NYSE: KVUE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Skillman, NJ based Kenvue Inc. operates as a consumer health company worldwide. Kenvue Inc. reported that its annual Total Revenue declined from over $15.05 billion in 2021 to over $14.95 billion in 2022, and that its Net Income increased from over $2.03 billion in 2021 to over $2.08 billion in 2022.

On May 08, 2023, Kenvue Inc. (NYSE: KVUE) announced the closing of its initial public offering ("IPO") of 198,734,444 shares of its common stock at a price to the public of $22.00 per share, including the underwriters' full exercise of their option to purchase 25,921,884 shares to cover over-allotments. Shares of Kenvue's common stock began trading on the New York Stock Exchange under the symbol "KVUE" on May 4, 2023.
Shares of Kenvue Inc. (NYSE: KVUE) rose in the open market to $27.80 per share on May 15, 2023.

The plaintiff claims that the Registration Statement contained false and/or misleading statements and/or failed to disclose that Kenvue faces potential headwinds as a result of confirmed concerns about the efficacy of phenylephrine, which it knew or should have known, that Kenvue did not discuss risks relating to the efficacy of phenylephrine (or "PE") in its IPO, the utility of which had been questioned since at least 2007, that while the Company disclosed risks relating to litigation, it did not disclose specific risk relating to potential litigation arising from adverse findings on the efficacy of phenylephrine, and that as a result, Defendants' public statements were materially false and misleading at all relevant times and negligently prepared.

Those who purchased shares of Kenvue Inc. (NYSE: KVUE) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.